Rectal leiomyosarcoma, three-year follow-up

Figueiredo, Juliano Alves; Andrade, André Felipe Zuccolo Barragat de; Carneiro, Bruno Gustavo Muzzi Carvalho e; Nogueira, Flávio Silva; Lage, Greiciane Parreiras

doi:10.1590/s2237-93632012000100010

Cited by 2 publications

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Rectal leiomyosarcoma is rare accounting for 0.1–0.5% of all malignant tumours of the rectum 5 6. There are only four other case reports of rectal leiomyosarcoma developing in the context of pelvic irradiation.…”

Section: Discussionmentioning

confidence: 99%

Rectal leiomyosarcoma: a rare and long-term complication of radiation therapy

et al. 2014

View full text Add to dashboard Cite

Leiomyosarcoma of the rectum can develop as a late complication in patients with a history of pelvic irradiation. We report the case of a patient who developed rectal leiomyosarcoma 13 years after receiving radiation for treatment of a stage 2 squamous cell cancer of the anus. This was detected on physical examination. Based on a discussion with the patient, we decided to manage conservatively. Overall, leiomyosarcomas constitute 5-12% of radiation-induced sarcomas. Rectal leiomyosarcoma is rare, accounting for 0.1-0.5% of all malignant tumours of the rectum. As radiation therapy plays a major role in the management of anal cancer, it is important that clinicians are aware of the possible development of radiation-induced sarcomas that may occur decades after initial management.

show abstract

Section: Discussionmentioning

confidence: 99%

Rectal leiomyosarcoma: a rare and long-term complication of radiation therapy

et al. 2014

View full text Add to dashboard Cite

show abstract

Gastrointestinal (GI) leiomyosarcoma (LMS) case series and review on diagnosis, management, and prognosis

et al. 2016

View full text Add to dashboard Cite

This review of 76 gastrointestinal (GI) leiomyosarcoma (LMS) cases that include 11 cases from the American University of Beirut Medical Center represents, to our knowledge, the largest number of combined GI LMS cases reported. The age range of GI LMS is variable, and the presentation is non-specific, making pathological diagnosis essential. LMSs usually lack CD117 and CD 34 mutations and are usually positive for smooth muscle cell markers. The review highlights surgery as the mainstay of treatment with negative margins attained most of the times. Adjuvant chemotherapy is used in around 7-27 % of the cases mainly for small intestinal and colorectal LMS. The relatively small number of patients is a limitation on outcome analysis. However, LMS has a risk of recurrence reaching 39-80 % and secondary metastasis reaching 55-71 % in small intestinal and colorectal cases. In light of the high frequency of recurrence and metastasis, enrolling patients in clinical randomized trials to investigate the role of chemotherapy, radiation therapy, and targeted therapy is required for better control of this rare aggressive GI tumor.

show abstract

Rectal leiomyosarcoma, three-year follow-up

Cited by 2 publications

References 6 publications

Rectal leiomyosarcoma: a rare and long-term complication of radiation therapy

Rectal leiomyosarcoma: a rare and long-term complication of radiation therapy

Gastrointestinal (GI) leiomyosarcoma (LMS) case series and review on diagnosis, management, and prognosis

Contact Info

Product

Resources

About